Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2026

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Mecapegfilgrastim

DRUG

dalpiciclib

DRUG

exemestane, fulvestrant, letrozole, tamoxifen

endocrine therapy

Trial Locations (1)

中山大学中山纪念医院, Guangzhou

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER